Tirzepatide Dosing: The FDA Label Schedules Explained

Almost every question people type about tirzepatide dosing has a published answer, and it is published in the same place for both products: the FDA-approved prescribing information. The schedule is not a secret, it is not a clinic's proprietary protocol, and it does not vary by telehealth brand. What varies is which product you were prescribed, which indication it carries, and what your clinician decides about your response and tolerability. This guide reports the label, line by line.

What Tirzepatide Is, and Why There Are Two Labels

Tirzepatide is a once-weekly subcutaneous injection described on its label as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. That dual-receptor description is the mechanistic difference between tirzepatide and the single-receptor GLP-1 agonists such as semaglutide. If you are comparing the two molecules rather than the dosing, our semaglutide vs tirzepatide comparison covers the differences, and the full list of GLP-1 medications maps which brand carries which indication.

Eli Lilly markets tirzepatide under two brand names with two separate FDA approvals and two separate prescribing information documents:

• Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. It is not FDA-approved for weight management.

The stacking question is answered on one of the two labels, not both. The Zepbound label carries a Limitation of Use in section 1: Zepbound contains tirzepatide, and coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. The Mounjaro label has no Limitations of Use section and states no such restriction. Reporting that difference accurately matters, because the two products are the same molecule and it is easy to assume the limitation is shared. Whether combining any two prescription medications is appropriate is a question for the prescriber, on either product.

Zepbound Dosage: The FDA Label Titration Schedule

The Zepbound prescribing information states that the recommended starting dosage for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks, and that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. After 4 weeks, the label describes increasing the dosage to 5 mg once weekly, with further increases in 2.5 mg increments after at least 4 weeks on the current dose.

The maintenance ranges are indication-specific, and this is the detail most summaries drop. For weight reduction and long-term maintenance, the Zepbound label lists a recommended maintenance dosage of 5 mg, 10 mg, or 15 mg once weekly. For obstructive sleep apnea, it lists 10 mg or 15 mg once weekly. The 7.5 mg and 12.5 mg strengths exist on the label as rungs on the ladder, not as listed maintenance dosages.

The label attaches two judgment clauses to the schedule. First: consider treatment response and tolerability when selecting the maintenance dosage. Second: if patients do not tolerate a maintenance dosage, consider a lower maintenance dosage. The written schedule is a ceiling and a floor, not a conveyor belt. Whether you move up, stay, or step down is a prescriber decision.

Mounjaro Dosage: The FDA Label Titration Schedule

The Mounjaro label specifies the same starting point and the same step size, with the escalation trigger written in diabetes terms. The recommended starting dosage is 2.5 mg injected subcutaneously once weekly, and the label states that the 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, the label describes increasing to 5 mg once weekly. If additional glycemic control is needed, the label describes increasing in 2.5 mg increments after at least 4 weeks on the current dose.

The Mounjaro label also carries an insulin-specific instruction absent from most consumer summaries: when used with insulin, administer as separate injections and never mix, and the label notes it is acceptable to inject in the same body region as long as the injections are not adjacent. The label further states that when initiating tirzepatide, consider reducing the dose of concomitantly administered insulin or insulin secretagogues such as sulfonylureas to reduce hypoglycemia risk. That is a prescriber instruction, and it is one reason dose changes on tirzepatide are not a solo decision when other glucose-lowering medications are involved.

Why Tirzepatide Dose Escalation Exists

The label states the reason plainly. Both the Zepbound and Mounjaro labels instruct clinicians to follow the dosage escalation schedule to reduce the risk of gastrointestinal adverse reactions. The four-week minimum interval is not an arbitrary billing cycle; it is the label's tolerability buffer.

The magnitude of that GI burden is documented in the Zepbound label's clinical trial experience. In a pool of two randomized, double-blind, placebo-controlled weight reduction trials in adults with obesity or overweight, gastrointestinal adverse reactions occurred in 56% of patients at each of the 5 mg, 10 mg, and 15 mg doses versus 30% on placebo. The most common individual reactions reported at a rate of at least 2% and greater than placebo were:

Source: ZEPBOUND prescribing information, Adverse Reactions (6.1), pooled Study 1 and Study 2. Rates observed in one drug's trials cannot be directly compared to another drug's trials.

Discontinuation follows the same pattern. Across those two trials, 4.8%, 6.3%, and 6.7% of patients on 5 mg, 10 mg, and 15 mg respectively permanently discontinued treatment due to adverse reactions, versus 3.4% on placebo, and the label notes the majority who discontinued did so during the first few months, driven by gastrointestinal reactions. That first-few-months window is exactly the window the titration schedule is designed to soften. For the full adverse-reaction picture beyond dosing, see our tirzepatide side effects guide.

What the Label Says About a Missed Dose of Tirzepatide

This is one of the highest-volume tirzepatide questions and the label answers it identically for both products. The instruction, verbatim in substance:

Two things are worth noticing. The label describes no catch-up dosing and no doubling, and the 72-hour minimum separation is what makes shifting your injection day possible without compressing two doses together. If you have missed a dose, the right move is to contact the prescriber or pharmacist who manages your therapy rather than to reason from a web page.

Vials, Single-Dose Pens, and KwikPens: The Presentations on the Label

The same milligram dose can arrive in physically different devices, and the label treats that as a safety issue rather than a packaging detail. Both the Zepbound and Mounjaro labels list the drug as available in pre-filled single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens, with the multi-dose vial and the KwikPen each containing four doses.

The label's administration instructions are explicit that the presentation itself requires training. Clinicians are told to inform patients which presentation they will receive, to ensure training appropriate to that specific presentation, and, if the prescribed presentation changes, to re-train and direct patients to the Instructions for Use for the new presentation. A vial-and-syringe regimen is not the same user task as a single-dose pen, and the label treats a switch between them as a re-training event.

Presentation is also the main place dosing and price intersect. Vial-based supply through direct-pay channels is generally cheaper per month than pen-based supply, which is why so many self-pay patients end up on vials. We break down what each route actually costs in our tirzepatide cost guide and in the cheapest GLP-1 without insurance comparison.

What Prescribers Consider When Choosing a Maintenance Dose

The label supplies the inputs. It does not supply an algorithm, because the maintenance decision is clinical. From the prescribing information itself, these are the factors the label puts in front of a clinician:

• Treatment response and tolerability. The Zepbound label instructs clinicians to consider both when selecting the maintenance dosage, and to consider a lower maintenance dosage if a patient does not tolerate the current one.
• Which indication is being treated. Weight reduction and long-term maintenance lists 5, 10, or 15 mg. Obstructive sleep apnea lists 10 or 15 mg only.
• Contraindications. The label contraindicates tirzepatide in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in patients with known serious hypersensitivity to tirzepatide or its excipients.
• Other glucose-lowering medications. The label says to consider reducing the dose of concomitant insulin or insulin secretagogues when initiating tirzepatide, to reduce hypoglycemia risk.
• Oral medications. The label notes tirzepatide delays gastric emptying and can affect the absorption of concomitantly administered oral medications, and advises caution.
• Severe gastroparesis. The label states tirzepatide is not recommended in patients with severe gastroparesis.
• Renal and hepatic function. The label states no dosage adjustment is recommended for renal impairment (including end-stage renal disease) or for hepatic impairment, while advising that renal function be monitored in patients reporting adverse reactions that could lead to volume depletion.

A program that never asks about any of this is worth a second look. When we compare telehealth GLP-1 programs in our best GLP-1 weight loss programs review, the clinical wrap around the prescription, meaning who titrates you, how often they check in, and what labs they run, is the variable that separates the programs more than the sticker price does. You can also browse GLP-1 and weight-loss clinics by state to see who is prescribing near you.

Compounded Tirzepatide and the Dosing-Error Problem

Compounded tirzepatide is not an FDA-approved product. It has not been evaluated by the FDA for safety, effectiveness, or quality, and it does not carry the FDA-approved prescribing information that defines the 2.5 mg start, the 2.5 mg steps, or the 15 mg maximum. Everything reported on this page describes the approved products.

The FDA has specifically warned about dosing errors with compounded GLP-1 products. The agency states it received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, resulting from patients measuring and self-administering incorrect doses and, in some cases, from health care professionals miscalculating doses. The agency also reports adverse events that may relate to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the FDA-approved label, which it describes as using more product in a single dose, taking doses more frequently, or increasing the amount more quickly than the titration schedule.

The FDA notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to the agency, so reports are likely undercounted. Even so, the FDA states that as of May 31, 2026 it had received more than 730 reports of adverse events associated with compounded tirzepatide and 990 reports associated with compounded semaglutide. The agency also says it is aware of fraudulent compounded semaglutide and tirzepatide carrying false label information, in some cases naming compounding pharmacies that do not exist.

What Dose Has to Do With Cost

A practical note that the label does not address. For the branded products, price is generally tied to the presentation and the supply channel rather than climbing with each milligram step, which means the escalation schedule does not automatically make month six more expensive than month one. Compounded programs frequently do price by dose, so a titration step can move the monthly number. That difference is worth understanding before you commit to a program.

We track real published prices rather than estimates in the tirzepatide cost guide and the semaglutide cost guide. If cost is the binding constraint, the cheapest GLP-1 without insurance comparison covers direct-pay vial channels and telehealth options side by side, and the oral GLP-1 pill guide covers the non-injectable route.

Keep reading

• The other molecule's schedule: semaglutide dosing guide
• Head to head: semaglutide vs tirzepatide
• Every approved GLP-1 and its indication: GLP-1 medications list
• Adverse reactions in detail: tirzepatide side effects and Ozempic side effects
• If a GLP-1 is not the right fit: Ozempic alternatives